In short
A groundbreaking clinical trial is underway to evaluate the safety and effectiveness of LY3884961, an innovative gene therapy for patients with Type 1 Gaucher Disease. This open-label, dose-finding study aims to assess the potential of this adeno-associated viral vector therapy in addressing the peripheral manifestations of Gaucher Disease. The trial involves carefully planned dose-finding and expansion periods, offering hope for improved treatment options for individuals living with this rare genetic disorder.
At a glance
- Study Drug
- LY3884961 (Adeno-Associated Viral Vector Serotype 9 Expressing Codon-Optimized Human GBA Gene)
- Condition
- Type 1 Gaucher Disease (Peripheral/Non-neuronopathic Manifestations)
- Study Design
- Open-label, Dose-Finding, Phase 1/2 Study
- Primary Objective
- Evaluate safety and tolerability of LY3884961
- Secondary Objectives
- Assess clinical and biomarker effects of LY3884961
- Key Eligibility Criteria
- Adults 18-65 years, confirmed bi-allelic GBA1 mutations, stable on ERT/SRT for ≥2 years
- Study Structure
- Dose-finding period (up to 3 cohorts of 3 patients) followed by expansion period (1 cohort of up to 6 patients)
- Key Endpoints
- Safety measures, changes in spleen volume, platelet count, GCase enzyme activity, and GluSph levels
What is LY3884961?
LY3884961 is an innovative gene therapy being developed for the treatment of Type 1 Gaucher Disease. It is also known by other names such as PR001A and AAV9.CBA.GBA1.A. This therapy is classified as an adeno-associated viral vector serotype 9 expressing codon-optimized human GBA gene. In simpler terms, it's a specially designed virus that carries a corrected version of the gene responsible for Gaucher Disease.
How Does LY3884961 Work?
LY3884961 works by using a harmless virus (AAV9) as a delivery vehicle to introduce a healthy copy of the GBA1 gene into the patient's cells. The GBA1 gene is responsible for producing an enzyme called glucocerebrosidase, which is deficient in people with Gaucher Disease. By providing a functional copy of this gene, the therapy aims to restore the production of the missing enzyme and potentially alleviate the symptoms of the disease.
Target Condition: Type 1 Gaucher Disease
LY3884961 is specifically designed to treat Type 1 Gaucher Disease, also known as non-neuronopathic Gaucher Disease. This is the most common form of Gaucher Disease, characterized by: Enlargement of the liver and spleen (hepatosplenomegaly) Low blood platelet counts (thrombocytopenia) Bone problems, including pain and fractures Anemia (low red blood cell count) Unlike other types of Gaucher Disease, Type 1 typically does not affect the brain or nervous system.
Clinical Trial Overview
The clinical trial for LY3884961 is an open-label, dose-finding Phase 1/2 study. It aims to evaluate the safety and tolerability of a single intravenous dose of the therapy in patients with Type 1 Gaucher Disease. The study is divided into two main periods:
- Dose Finding Period: This involves up to three cohorts, each with 3 patients. There's a 4-week gap between patients to allow for safety review.
- Expansion Period: One cohort of up to 6 patients will receive the optimal dose determined in the first period.
Eligibility Criteria
To participate in this study, patients must meet certain criteria. Some key inclusion criteria are:
- Age 18-65 years
- Confirmed bi-allelic GBA1 mutations
- On stable enzyme replacement therapy (ERT) or substrate reduction therapy (SRT) for at least 2 years
Some exclusion criteria include:
- Significant neurological symptoms
- Severe splenomegaly (enlarged spleen)
- History of total splenectomy
- Severe thrombocytopenia (low platelet count)
- Previous gene or cell therapy
Study Objectives and Endpoints
The main objective of this study is to evaluate the safety and tolerability of LY3884961. Secondary objectives include assessing its clinical and biomarker effects. Some key endpoints being measured are:
- Incidence and severity of treatment-emergent adverse events
- Changes in complement proteins and antibodies
- Changes in spleen volume
- Changes in platelet count
- Changes in enzyme activity and protein levels
Potential Benefits and Risks
While LY3884961 shows promise as a potential one-time treatment for Type 1 Gaucher Disease, it's important to understand that it's still in the experimental stage. Potential benefits could include improved enzyme function and reduction in disease symptoms. However, as with any gene therapy, there are risks to consider, such as immune reactions or unexpected effects of the viral vector.
It's crucial for patients to discuss the potential benefits and risks thoroughly with their healthcare providers and the study team before considering participation in this clinical trial.